Clinical Research & New Drugs
Large clinical trials, new treatments, and vaccine and diagnostic research
11 stories
Obinutuzumab β, a type II anti-CD20 antibody that depletes B cells, greatly reduced 1-year relapses in patients with AQP4 antibody-positive neuromyelitis optica.
Final results show that adding the bispecific antibody to chemotherapy improved overall survival in EGFR-mutant lung cancer that progressed after targeted therapy.
In a trial of 5,420 newborns under 2 kg in neonatal intensive care units in India, neonatal deaths fell in the group vaccinated right after birth.
As first-line treatment for obstructive hypertrophic cardiomyopathy, aficamten alone improved exercise capacity and symptoms more than metoprolol alone.
Adding AI to Germany's national breast cancer screening raised the cancer detection rate without increasing recalls.
Lenacapavir, given every six months, allowed no new HIV infections in a phase 3 trial of young women in South Africa and Uganda.
A therapy that edits a patient's blood stem cells with gene scissors to revive fetal haemoglobin nearly eliminated vaso-occlusive crises in a phase 3 trial.
Compared with colonoscopy, a blood cfDNA test found 83% of colorectal cancers but caught only 13% of precancerous lesions.
Zilebesiran, which switches off angiotensinogen production in the liver, lowered systolic blood pressure by more than 14 mmHg compared with placebo in a phase 2 trial in mild to moderate hypertension.
The low-cost malaria vaccine R21/Matrix-M showed high efficacy in a phase 3 trial of about 4,800 African children.
In a randomised, double-blind trial, the body fat percentage and body fat mass of the group taking the extract fell significantly more than in the placebo group.